Add like
Add dislike
Add to saved papers

Extraskeletal Mesenchymal Chondrosarcoma of Shoulder: An Extremely Rare Case.

INTRODUCTION: Extraskeletal chondrosarcoma (EMC) is a rare, aggressive neoplasm which has been seen in the soft tissue area. This soft tissue sarcoma is classified to myxoid and mesenchymal based on histologic criteria. The mesenchymal subtype has a poor prognosis. In approximately 50% of patient with EMC, we could observe soft tissue lesion and stippled calcification in the conventional radiography.

CASE REPORT: In the current paper, we introduced a 47-year-old Iranian male patient having painless, mobile, nontender, and firm mass in left shoulder. We did not find neurovascular disturbance at the upper extremity, and the patient had a full range of motion in the left shoulder. The tumor was treated with wide resection and followed by radiation therapy.

CONCLUSION: Complete wide resection of mesenchymal chondrosarcoma could be enough as an initial treatment and chemotherapy reserved for patients that have unresectable masses. Apparently, the main key in the treatment is the surgical resection, and this process is the most important method in their management.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app